| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka |
NCT00652054: Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer |
|
|
| Completed | 2 | 39 | NA | S-1 | Taiho Oncology, Inc., Quintiles, Inc. | Secondary Malignant Neoplasm of Pancreas | 06/07 | 10/07 | | |
NCT00436423: A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer |
|
|
| Completed | 2 | 38 | RoW | gemcitabine, TS-1 | Korea University Anam Hospital, Seoul National University Hospital, Seoul Municipal Boramae Hospital, Konkuk University Hospital, Korea University Ansan Hospital, Seoul National University Bundang Hospital, Korea University Guro Hospital | Pancreatic Neoplasm, Neoplasm Metastasis | | | | |
| Completed | 2 | 110 | Japan | gemcitabine + S-1, gemzar, TS-1, gemcitabine | Japan Clinical Cancer Research Organization | Pancreatic Cancer | 08/10 | 12/10 | | |
|
|
NCT01430052: Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer |
|
|
| Completed | 2 | 110 | Japan | Drug: gemcitabine, S-1, gemzer, TS-1, gemcitabine, S-1, radiotherapy | Osaka Medical Center for Cancer and Cardiovascular Diseases | Pancreatic Cancer | 12/12 | 09/15 | | |
NCT00209677: Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer |
|
|
| Suspended | 1/2 | 40 | Japan | Gemcitabine, S-1 | Hokkaido Gastrointestinal Cancer Study Group, Hokkaido University Hospital | Pancreatic Cancer | | 12/07 | | |
NCT01781520: Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer |
|
|
| Completed | 1/2 | 47 | RoW | DC-CIK Treatment, S1, Best supportive care | Capital Medical University | Pancreatic Cancer | 05/16 | 06/17 | | |
